Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) Sees Large Decrease in Short Interest

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) was the target of a significant decline in short interest in March. As of March 31st, there was short interest totalling 6,600 shares, a decline of 68.7% from the March 15th total of 21,100 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily volume of 58,400 shares, the short-interest ratio is presently 0.1 days.

Inhibitor Therapeutics Stock Performance

Shares of OTCMKTS:INTI remained flat at $0.05 during mid-day trading on Tuesday. The company’s 50 day moving average price is $0.06 and its 200 day moving average price is $0.07. The company has a market cap of $8.67 million, a PE ratio of -5.02 and a beta of -0.61. Inhibitor Therapeutics has a 1 year low of $0.04 and a 1 year high of $0.14.

Inhibitor Therapeutics (OTCMKTS:INTI) last posted its quarterly earnings data on Friday, March 28th. The company reported ($0.01) earnings per share for the quarter.

Inhibitor Therapeutics Company Profile

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.